Please read more on news & testimonies About CIMAvax EGF
Roswell Park Comprehensive Cancer Center
Roswell Park Comprehensive Cancer Center is leading the nation in bringing a lung cancer therapy developed in Cuba to the United States. The Roswell Park Alliance Foundation has committed donated funds to enable the rapid startup of the initial clinical trials of the immunotherapy treatment.
You can be a part of our commitment to help bring CIMAvax to the bedsides of lung cancer patients at Roswell Park, and across the country, as quickly as possible.
Proof already exists that it works for many patients. But, we need continued philanthropic support to further test the immunotherapy at Roswell Park so that we can improve the treatment of lung cancer and maintain the momentum of this important historic initiative.
Your support gives hope to lung cancer patients, especially those at high risk for recurrence. And, with your help, Roswell Park will be closer to investigating other potential uses of CIMAvax-- not only for advanced lung cancer, but also for patients at high risk for developing lung cancer and applications for other disease sites, starting with colon, head and neck, prostate, breast and pancreatic cancers.
Roswell Park Comprehensive Cancer Center is leading the nation in bringing a lung cancer therapy developed in Cuba to the United States. The Roswell Park Alliance Foundation has committed donated funds to enable the rapid startup of the initial clinical trials of the immunotherapy treatment.
CONTINUE READING
What to Know About the CIMAvax Lung Cancer Vaccine
CIMAvax is a vaccine against a molecule called EGFR, which is highly expressed in some patients with lung cancer.(Getty Images)
Someday, we may have a vaccine that prevents all types of cancer, especially the more deadly types, like lung cancer. It's an area of intense medical research. For now, there are only three cancer vaccines approved by the U.S. Food and Drug Administration. However, you may have read news articles about a vaccine developed for lung cancer in Cuba called CIMAvax. Here's what to know about this drug.
[See: 7 Innovations in Cancer Therapy.]
What Is a Cancer Vaccine?
The immune system helps fight things that could make you sick, such as bacteria or viruses. A vaccine boosts your immune system's ability to do this. This is important because cancer has ways to trick the immune system so it doesn't recognize tumor cells as harmful or doesn't attack cancer cells even if it recognizes them as a threat.
Cancer vaccines are called biological response modifiers because they stimulate or restore the immune system's ability to fight infection and disease, according to the National Cancer Institute. Cancer vaccines can help prevent cancer from developing (preventive or prophylactic vaccines) or help treat cancer once it has developed.
CONTINUE READING
Why an American people went to Cuba for cancer care
Cuba has faced more than 50 years of US sanctions. Now, for the first time, a unique drug developed on the communist island is being tested in New York state. But some American cancer patients are already taking it - by defying the embargo and flying to Havana for treatment.
Judy Ingels and her family are in Cuba for just six days. They have time to go sightseeing and try out the local cuisine. Judy, a keen photographer, enjoys capturing the colonial architecture of Old Havana.
And while she is in the country, Ingels, 74, will have her first injections of Cimavax, a drug shown in Cuban trials to extend the lives of lung cancer patients by months, and sometimes years.
By travelling to Havana from her home in California, she is breaking the law.
The US embargo against Cuba has been in place for more than five decades, and though relations thawed under President Obama, seeking medical treatment in Cuba is still not allowed for US citizens.
"I'm not worried," Ingels says. "For the first time I have real hope."
Cuban Cancer Immunotherapies Coming to the USA
October 2nd, 2018 – New York-based Roswell Park Comprehensive Cancer Center has formed the first-ever biotech venture between the U.S. and Cuba.
This new joint venture gives Roswell Park access to CIMAvax and additional Cuban-developed cancer immunotherapy treatments not previously accessible to U.S. patients or researchers.
Following a 2015 trade mission, Roswell Park became the first medical institution to initiate FDA-authorized testing of CIMAvax-EGF in the United States.
CIMAvax is a Cuban-developed lung cancer treatment currently in a phase 1 US clinical study. The initiation of the phase II study is anticipated for late 2018.
Recommended:
Discounts Appointments Clinical Trials Lab Tests
The Cuban phase II and phase III clinical trials of CIMAvax have shown increased overall survival and improvement in the quality of life for patients with non-small cell lung cancer.
These Cuban immunotherapies are innovative treatment approaches designed to enhance the body’s innate cancer-fighting self-defense system, alone or in combination with other immunotherapies.
While these agents are still investigational therapies in the United States, evidence to date strongly suggests that all four are worthy of further study in several cancer types.
CONTINUE READIMNG
Lung cancer patient says she's now in remission thanks to Cuban vaccine
A Regina woman who was diagnosed with lung cancer and given a year to live says she’s now in remission thanks to a vaccine she received in Cuba.
Judy Bryden, who received the devastating diagnosis in 2016, travelled to Cuba last year to receive treatment and pick up several doses of the CIMAvax EGF vaccine. The vaccine was developed for non-small cell lung cancer, which represents up to 85 per cent of all lung cancers.
After taking the vaccine doses over several months, Bryden said a recent scan of her lungs found no cancer.
“When they told me I had a year to live, I said I was going to prove them wrong,” Bryden told CTV Regina. “I didn't know how, but I was going to prove them wrong.”
She wishes that CIMAvax was available in Canada for other patients like her who have run out of treatment options.
After her diagnosis, Bryden underwent chemotherapy and five radiation treatments, which failed to halt the progress of her cancer. When her husband, Lorne Bryden, started searching online for other treatment options, he learned about CIMAvax.
The vaccine works by triggering the patient’s own immune system to produce antibodies against a protein linked to growth and multiplication of cancer cells. Studies have suggested that CIMAvax can prolong survival time for non-small cell cancer patients. One clinical trial found that long-term administration of CIMAvax was “very safe.”
CONTINUE READING
CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer
Epidermal growth factor receptor (EGFR) is overexpressed in many epithelial tumors and its role in the development of non-small-cell lung cancer (NSCLC) is widely documented. CIMAvax-EGF is a therapeutic cancer vaccine composed by recombinant EGF conjugated to a carrier protein and emulsified in Montanide ISA51.
Epidermal growth factor receptor (EGFR) is overexpressed in many epithelial tumors and its role in the development of non-small-cell lung cancer (NSCLC) is widely documented. CIMAvax-EGF is a therapeutic cancer vaccine composed by recombinant EGF conjugated to a carrier protein and emulsified in Montanide ISA51. Vaccination induces antibodies against self-EGF that block EGF–EGFR interaction and inhibit EGFR phosphorylation. Five clinical trials were conducted to optimize vaccine formulation and schedule. Then, two randomized studies were completed in advanced NSCLC, where CIMAvax-EGF was administered after chemotherapy, as ‘switch maintenance’. The vaccine was very well tolerated and the most frequent adverse events consisted of grade 1/2 injection site reactions, fever, headache, vomiting and chills. CIMAvax was immunogenic and EGF concentration was reduced after vaccination. Subjects receiving a minimum of 4 vaccine doses had a significant survival advantage. NSCLC patients with high EGF concentration at baseline had the largest benefit, comparable with best maintenance therapies.
CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer
You can browse for CIMAvax-EGF online Pages
[23/1 9:46 p. m.] Haymee Santos Valdés:
https://clinicaltrials.gov/ct2
[23/1 9:47 p. m.] Haymee Santos Valdés:
https://health.usnews.com/heal
[23/1 9:47 p. m.] Haymee Santos Valdés:
https://www.precisionvaccinati
[23/1 9:50 p. m.] Haymee Santos Valdés: This arricle i think its vwry
important because its the use cimavax in some types of cancer too
https://www.google.com/url?q=h
[23/1 9:51 p. m.] Haymee Santos Valdés:
https://m.youtube.com/watch?v=
[23/1 9:51 p. m.] Haymee Santos Valdés:
CONTINUE READING
